Somewhat Positive Press Coverage Somewhat Unlikely to Impact Integra Lifesciences (IART) Stock Price
News coverage about Integra Lifesciences (NASDAQ:IART) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Integra Lifesciences earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the life sciences company an impact score of 46.6683247068972 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Integra Lifesciences (IART) traded up $0.76 during midday trading on Thursday, reaching $52.93. The company’s stock had a trading volume of 366,769 shares, compared to its average volume of 504,421. Integra Lifesciences has a 12-month low of $40.51 and a 12-month high of $56.42. The firm has a market capitalization of $4,160.00, a PE ratio of 86.77, a P/E/G ratio of 1.65 and a beta of 0.67. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39.
A number of research analysts recently commented on the company. BidaskClub raised Integra Lifesciences from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Oppenheimer reissued a “buy” rating on shares of Integra Lifesciences in a report on Thursday, October 26th. Zacks Investment Research downgraded Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Barclays reissued a “hold” rating and issued a $53.00 price target on shares of Integra Lifesciences in a report on Tuesday, January 9th. Finally, TheStreet raised Integra Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $52.70.
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.